TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33957257

Group type: EXPERIMENTAL
Intervention: ATLS Training
Number of subjects: 1030
Study: 35452339

Group type: EXPERIMENTAL
Intervention: tDCS with anode over the right cerebellum (O2) and cathode over the supplementary motor area (pre-SMA; c3/c4)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: tDCS with anode over O2 and cathode over the left OFC (FP1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: tDCS with anode over O2 and cathode over the left cerebellum (O1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham stimulation (anode over O2 and cathode over the left FP1)
Number of subjects: 40
Study: 35501751

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (15 mg/kg before incision and 1 mg/kg/hour during operation)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (placebo: 0.9% sodium chloride solution)
Number of subjects: 68
Study: 32367879

Group type: EXPERIMENTAL
Intervention: 17% EDTA
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.2% chitosan
Number of subjects: 45

Group type: COMPARATOR
Intervention: 10% trisodium citrate
Number of subjects: 45
Study: 34029605

Group type: EXPERIMENTAL
Intervention: Dorsal onlay urethroplasty
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ventral onlay urethroplasty
Number of subjects: 24
Study: 33962567

Group type: EXPERIMENTAL
Intervention: Prolonged TV viewing time (≥4 h/day)
Number of subjects: 2752

Group type: EXPERIMENTAL
Intervention: Not working
Number of subjects: 2752

Group type: EXPERIMENTAL
Intervention: Lower education attainment
Number of subjects: 2752

Group type: EXPERIMENTAL
Intervention: Living status
Number of subjects: 2752

Group type: EXPERIMENTAL
Intervention: EHE
Number of subjects: 2752
Study: 32201056

Group type: EXPERIMENTAL
Intervention: Spherical silicone hydrogel contact lenses (comfilcon A)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Aspheric silicone hydrogel contact lenses (comfilcon A)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Comparison between spherical and aspheric lenses
Number of subjects: 68
Study: 34374961

Group type: EXPERIMENTAL
Intervention: LDP + NPX (carbidopa/levodopa and naproxen)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo + naproxen
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: LDP + NPX
Number of subjects: 72
Study: 35092886

Group type: EXPERIMENTAL
Intervention: Parent-based intervention (PBI) with alcohol-related content; n = 44
Number of subjects: 82

Group type: COMPARATOR
Intervention: Parent-based intervention (PBI) without alcohol-related content; n = 38
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Living with parents
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Moving out of parents' home
Number of subjects: 82
Study: 33828046

Group type: EXPERIMENTAL
Intervention: Supervised ground‐based walking training, performed two to three times/week, for 8‐10 weeks.
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Pre-training ESWT at a faster walking speed.
Number of subjects: 77
Study: 35500978

Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy + PNF exercises (n = 15)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy + SM techniques (n = 15)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional physiotherapy (control group; n = 14)
Number of subjects: 44
Study: 33143502

Group type: EXPERIMENTAL
Intervention: Platelet transfusion directed at platelet dysfunction
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Platelet functional assays
Number of subjects: 348
Study: 616117228

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1185
Study: 35108463

Group type: EXPERIMENTAL
Intervention: Music intervention (n=35)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (n=35)
Number of subjects: 70
Study: 33838518

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Continuation of amisulpride
Number of subjects: 288

Group type: COMPARATOR
Intervention: Switch to olanzapine
Number of subjects: 288
Study: 36062851

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg every 21 days for 16 cycles or 1 year)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Atezolizumab
Number of subjects: 149
Study: 34909951

Group type: COMPARATOR
Intervention: Oxybutynin 5 mg/day (Group O)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg/day (Group M)
Number of subjects: 0
Study: 35920129

Group type: EXPERIMENTAL
Intervention: Test group 2 (RMNES at the same time as HBOT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Test group 1 (RMNES after HBOT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups (EEG, BAEP, USEP)
Number of subjects: 120
Study: 33688992

Group type: EXPERIMENTAL
Intervention: Silicone-hydrocoated ureteral stents (Coloplast Imajin® hydro)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Percuflex™ Plus stent (Boston Scientific)
Number of subjects: 141
Study: 32316957

Group type: EXPERIMENTAL
Intervention: Peer-led school-based walking intervention (10-15 min walks led by older female pupils before school, at break, and lunch for a minimum of 20-22 weeks)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Peer-led school-based walking intervention
Number of subjects: 18
Study: 33517316

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with anthracycline followed by paclitaxel, RDI ≥85%
Number of subjects: 188

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NAC) with anthracycline followed by paclitaxel, RDI <85%
Number of subjects: 188
Study: 32410260

Group type: EXPERIMENTAL
Intervention: PRIMA‐PI high-risk group
Number of subjects: 291

Group type: COMPARATOR
Intervention: FLIPI risk groups
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: PRIMA‐PI
Number of subjects: 291
Study: 35286033

Group type: EXPERIMENTAL
Intervention: melatonin 5mg/kg/day per gastric tube for 3 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: surfactant with the INSURE technique
Number of subjects: 80
Study: 35668430

Group type: EXPERIMENTAL
Intervention: self‐efficacy‐enhancing physical activity intervention
Number of subjects: 244

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 244
Study: 33071237

Group type: EXPERIMENTAL
Intervention: PRT + metformin (metPRT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: PRT with placebo (plaPRT)
Number of subjects: 47
Study: 34902765

Group type: EXPERIMENTAL
Intervention: Palbociclib plus Fulvestrant
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo plus Fulvestrant
Number of subjects: 190
Study: 35614158

Group type: EXPERIMENTAL
Intervention: One preoperative showering with CHG 4% (Group B)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Two preoperative showering with CHG 4% (Group C)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No preoperative showering (Group A)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Comparison of skin concentration at different sites
Number of subjects: 45
Study: 33153986

Group type: EXPERIMENTAL
Intervention: Completion of PROMs at home (paper-and-pencil format)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Completion of PROMs at hospital
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Overall preference for completion method
Number of subjects: 93
Study: 36315523

Group type: EXPERIMENTAL
Intervention: i-MaCHeL intervention programme (classroom activities for children and web-based educational programme for parents)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Control group (existing health-related activities for children and general health newsletters for parents)
Number of subjects: 460
Study: 32895969

Group type: EXPERIMENTAL
Intervention: Home-delivered, protein-rich meal service (6 protein-rich dishes per day for 3 weeks)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 126
Study: 35079806

Group type: EXPERIMENTAL
Intervention: Nutrient compendium snacks containing ≥5 g fiber, 1000 mg ω‐3 fatty acids, 1000 mg phytosterols, and 1800 μmol antioxidants per serving.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control products (calorie-matched like-items from the general grocery marketplace).
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Nutrient compendium snacks
Number of subjects: 54
Study: 34399585

Group type: EXPERIMENTAL
Intervention: Antihypertensive drug classes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipid-lowering drug classes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticoagulant drug classes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel drug targets for inflammatory pathways
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel drug targets for coagulation cascade
Number of subjects: 0
Study: 34707169

Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention aimed at strengthening muscles and improving prosthesis adaptation.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (participants with amputation who did not receive the intervention).
Number of subjects: 26
Study: 33408462

Group type: EXPERIMENTAL
Intervention: Half-dose triple combination (amlodipine 2.5 mg + losartan 25 mg + chlorthalidone 6.25 mg)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Third-dose triple combination (amlodipine 1.67 mg + losartan 16.67 mg + chlorthalidone 4.17 mg)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Quarter-dose triple combination (amlodipine 1.25 mg + losartan 12.5 mg + chlorthalidone 3.13 mg)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study: 35835521

Group type: EXPERIMENTAL
Intervention: Soft palatal augmentation prosthesis (PAP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rehabilitation using soft PAP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional rehabilitation without soft PAP
Number of subjects: 0
Study: 33745452

Group type: EXPERIMENTAL
Intervention: Fibrin glue (1 cc of IFABOND® applied to the surgical bed)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no fibrin glue)
Number of subjects: 80
Study: 32616256

Group type: EXPERIMENTAL
Intervention: Basal diet with 2-fold supplementation level of water-soluble vitamins (WV)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Basal diet with 2-fold supplementation level of lipid-soluble vitamins (LV)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Basal diet with 2-fold supplementation level of both lipid-soluble and water-soluble vitamins (BV)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Basal diet (CON)
Number of subjects: 300
Study: 35604794

Group type: COMPARATOR
Intervention: Masked continuous glucose monitoring (CGM) over 14 days during baseline
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Open continuous glucose monitoring (CGM) over 14 days after randomization
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Overall diagnostic performance of hypoglycemic parameters
Number of subjects: 288
Study: 33985848

Group type: EXPERIMENTAL
Intervention: Orogastric intubation (OGI)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nasogastric intubation (NGI)
Number of subjects: 12
Study: 35050357

Group type: COMPARATOR
Intervention: In-person DOT
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Electronic DOT
Number of subjects: 216
Study: 33647172

Group type: EXPERIMENTAL
Intervention: Invasive management with coronary angiography (CA)
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Invasive management
Number of subjects: 1052
Study: 32928328

Group type: EXPERIMENTAL
Intervention: CarbonCool cooling vest
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no cooling vest)
Number of subjects: 23
Study: 36246973

Group type: EXPERIMENTAL
Intervention: Ankle muscle strength training for 6 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ankle muscle strength training and ankle proprioception training
Number of subjects: 16
Study: 33927176

Group type: EXPERIMENTAL
Intervention: Preventive Group (saline hydration given 6 h before until 12 h after the procedure)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Remedial Group (saline hydration given after procedure for 12 h)
Number of subjects: 144

Group type: COMPARATOR
Intervention: No Hydration (NH) Group (saline given only during the procedure)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Preventive Group
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Remedial Group
Number of subjects: 144

Group type: COMPARATOR
Intervention: No Hydration (NH) Group
Number of subjects: 144
Study: 33008699

Group type: EXPERIMENTAL
Intervention: Three-dimensional printed ear splint therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35332042

Group type: EXPERIMENTAL
Intervention: Intelligent system evaluation for gait disorders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinicians' routine treatment procedures
Number of subjects: 0
Study: 32829596

Group type: EXPERIMENTAL
Intervention: Drug therapy combined with vestibular rehabilitation training (Experimental group)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Drug therapy (Control group)
Number of subjects: 43
Study: 35987698

Group type: EXPERIMENTAL
Intervention: High-flow nasal therapy (HFNT)
Number of subjects: 850

Group type: COMPARATOR
Intervention: Standard oxygen therapy (SOT)
Number of subjects: 850
Study: 32453885

Group type: EXPERIMENTAL
Intervention: Covariate-adaptive randomization (CAR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Covariate-adaptive randomization (CAR) with misclassified covariates adjusted in the model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two sample t-test
Number of subjects: 0
Study: 35287487

Group type: EXPERIMENTAL
Intervention: Managing Fatigue: Individual Program (MFIP) delivered via videoconference
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 54
Study: 32295565

Group type: EXPERIMENTAL
Intervention: Minocycline as adjunctive treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 100
Study: 35472112

Group type: EXPERIMENTAL
Intervention: BC combined with Emdogain (EMD+BC)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Alloplastic bone substitute (BoneCeramic [BC])
Number of subjects: 21

Group type: COMPARATOR
Intervention: Spontaneous healing (SO)
Number of subjects: 21
Study: 35044568

Group type: EXPERIMENTAL
Intervention: Asian insulin-naïve participants
Number of subjects: 4750

Group type: EXPERIMENTAL
Intervention: Asian insulin-experienced participants
Number of subjects: 4750
Study: 33799486

Group type: EXPERIMENTAL
Intervention: Aquamin®
Number of subjects: 30

Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 32175973

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Combined training
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: All training groups combined (subgroup analysis)
Number of subjects: 185
Study: 36191986

Group type: EXPERIMENTAL
Intervention: ICIs plus chemotherapy (chemoimmunotherapy)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: ICIs plus chemotherapy (chemoimmunotherapy) with prior brain radiotherapy
Number of subjects: 103
Study: 36180164

Group type: EXPERIMENTAL
Intervention: Mental Practice
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study: 34497852

Group type: EXPERIMENTAL
Intervention: Dapagliflozin adjunct to continuous subcutaneous insulin infusion (CSII)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 66
Study: 33965556

Group type: EXPERIMENTAL
Intervention: Task-oriented training combined with aerobic training (TOT-AT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aerobic training (AT)
Number of subjects: 40
Study: 32859666

Group type: EXPERIMENTAL
Intervention: Home-based, face-to-face, individually tailored activity and exercise programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in intervention delivery due to COVID-19
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remote support for therapy programme
Number of subjects: 0
Study: 34749395

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin plus bendamustine and rituximab (pola + BR)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Bendamustine and rituximab (BR)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin plus bendamustine and rituximab (pola + BR) in extension cohort
Number of subjects: 192
Study: 33792547

Group type: EXPERIMENTAL
Intervention: Slip Buddy app
Number of subjects: 64

Group type: COMPARATOR
Intervention: Calorie tracking app
Number of subjects: 64
Study: 33060179

Group type: EXPERIMENTAL
Intervention: Identification of biological motion (BM) actions by the CC group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coherent motion (CM) detection task by the CC group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vision matched (VM) control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sighted control (SC) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Developmental cataract (DC) reversal individuals (DC group)
Number of subjects: 0
Study: 35572961

Group type: EXPERIMENTAL
Intervention: Electro-Thumbtack Needle (ETN) therapy administered three times a week for four consecutive weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: Sham ETN therapy administered three times a week for four consecutive weeks
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Electro-Thumbtack Needle (ETN) therapy
Number of subjects: 180

Group type: COMPARATOR
Intervention: Sham ETN therapy
Number of subjects: 180
Study: 33214593

Group type: EXPERIMENTAL
Intervention: Self‐Assembling Peptide P11‐4 (SAP P11‐4)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Combination of SAP P11‐4 and delayed FV after 90 days
Number of subjects: 2

Group type: COMPARATOR
Intervention: Fluoride varnish (FV)
Number of subjects: 2
Study: 35783486

Group type: EXPERIMENTAL
Intervention: Trimer 4571 adjuvanted with 500 mcg alum, administered subcutaneously or intramuscularly at weeks 0, 8, and 20 in doses of 100 mcg or 500 mcg
Number of subjects: 16
Study: 32979986

Group type: EXPERIMENTAL
Intervention: Fevipiprant 150 mg
Number of subjects: 1771

Group type: EXPERIMENTAL
Intervention: Fevipiprant 450 mg
Number of subjects: 1771

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1771
Study: 32659437

Group type: EXPERIMENTAL
Intervention: SMS PA Advisor
Number of subjects: 350

Group type: COMPARATOR
Intervention: Telephone PA Advisor
Number of subjects: 350

Group type: COMPARATOR
Intervention: SMS Nutrition Advisor
Number of subjects: 350
Study: 34237271

Group type: EXPERIMENTAL
Intervention: RO7049389 200 mg twice a day
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: RO7049389 400 mg twice a day
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: RO7049389 200 mg once a day
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: RO7049389 600 mg once a day
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: RO7049389 1000 mg once a day
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 35687059

Group type: EXPERIMENTAL
Intervention: Norepinephrine bolus at 0.10 μg/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Norepinephrine bolus at 0.05 μg/kg
Number of subjects: 120
Study: 32876804

Group type: EXPERIMENTAL
Intervention: Nigella sativa oil (2000 mg/day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 33269511

Group type: COMPARATOR
Intervention: TRS-HFDM score 0
Number of subjects: 5123

Group type: COMPARATOR
Intervention: TRS-HFDM score 1
Number of subjects: 5123

Group type: COMPARATOR
Intervention: TRS-HFDM score 2
Number of subjects: 5123

Group type: COMPARATOR
Intervention: TRS-HFDM score 3
Number of subjects: 5123

Group type: COMPARATOR
Intervention: TRS-HFDM score 4+
Number of subjects: 5123

Group type: COMPARATOR
Intervention: TRS-HFDM overall
Number of subjects: 5123

Group type: COMPARATOR
Intervention: TRS-HFDM in participants without baseline HF
Number of subjects: 5123
Study: 35904638

Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation combined with enteral nutrition
Number of subjects: 108

Group type: COMPARATOR
Intervention: Routine nursing without enteral nutrition
Number of subjects: 108
Study: 34844551

Group type: EXPERIMENTAL
Intervention: Secnidazole 2.0 g po followed by Azithromycin 500 mg on day 1 continuing by 250 mg on days 2-7
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Secnidazole 2.0 g po followed by Josamycin 1000 mg bid for 12 days
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Secnidazole 2.0 g po followed by Moxifloxacin 400 mg once daily for 12 days
Number of subjects: 154
Study: 34047715

Group type: EXPERIMENTAL
Intervention: Home-centered activity-based therapy (parent-supervised) in addition to institutional physiotherapy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Ongoing institutional physiotherapy alone
Number of subjects: 59
Study: 33183345

Group type: EXPERIMENTAL
Intervention: Active TMS with BCBT
Number of subjects: 130

Group type: COMPARATOR
Intervention: Sham TMS with BCBT
Number of subjects: 130
Study: 35856722

Group type: EXPERIMENTAL
Intervention: Patient education regarding fasting recommendations (eat until 6 hours and drink until 2 hours before EGD)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 109
Study: 33543507

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine (CHX) rinse
Number of subjects: 69

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 69
Study: 32287316

Group type: EXPERIMENTAL
Intervention: P60.4Ac-containing ototopical drops (0.25-2.0 mg of peptide/ml)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 34
Study: 35384460

Group type: EXPERIMENTAL
Intervention: Combined predictive model based on MR Rad-S and clinical risk factors
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Clinical model
Number of subjects: 434

Group type: COMPARATOR
Intervention: Radiomics model
Number of subjects: 434